{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:22:23Z","timestamp":1780064543519,"version":"3.54.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fabry disease is an X-linked inherited metabolic condition where the deficit of the \u03b1-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. To date, more than 600 mutations have been identified in human GLA gene that are responsible for FD, including missense and nonsense mutations, small and large deletions. Such mutations are usually inherited, and cases of <jats:italic>de novo<\/jats:italic> onset occur rarely.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>In this article we report an interesting case of a 44-year-old male patient suffering from a severe form of Fabry disease, with negative family history. The patient showed signs such as cornea verticillata, angiokeratomas, cardiac and neurological manifestations, an end-stage renal disease and he had low \u03b1-galactosidase A activity. We detected, in this subject, the mutation c.493\u00a0G\u2009&gt;\u2009C in the third exon of the GLA gene which causes the amino acid substitution D165H in the protein. This mutation affects the amino acid - belonging to the group of buried residues - involved, probably, in the preservation of the protein folding. Moreover, studies of multiple sequence alignment indicate that this amino acid is highly conserved, thus strengthening the hypothesis that it is a key amino acid to the enzyme functionality.<\/jats:p>\n            <jats:p>The study of the relatives of the patient showed that, surprisingly, none of the members of his family of origin had this genetic alteration, suggesting a <jats:italic>de novo<\/jats:italic> mutation. Only his 11-year-old daughter - showing acroparaesthesias and heat intolerance with reduced enzymatic activity - had the same mutation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We suggest that a non-inherited mutation of the \u03b1-galactosidase A gene is responsible for Fabry disease in the patient who had reduced enzyme activity and classical clinical manifestations of the disease. In a family, it is rare to find only one Fabry disease affected subject with a <jats:italic>de novo<\/jats:italic> mutation. These findings emphasize the importance of early diagnosis, genetic counselling, studying the genealogical tree of the patients and starting enzyme replacement therapy to prevent irreversible vital organ damage that occurs during the course of the disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-0500-7-11","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T16:01:21Z","timestamp":1389110481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["De novo mutation in a male patient with Fabry disease: a case report"],"prefix":"10.1186","volume":"7","author":[{"given":"Francesco","family":"Iemolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Albeggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Zizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Colomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Scalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Bartolotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Duro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"key":"2588_CR1","doi-asserted-by":"crossref","unstructured":"Germain DP: Fabry disease. Orphanet J Rare Dis. 2010, 5 (30):","DOI":"10.1186\/1750-1172-5-30"},{"key":"2588_CR2","first-page":"3733","volume-title":"The Metabolic and Molecular Basis of Inherited Disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA: \u03b1-galactosidase a deficiency: fabry disease. The Metabolic and Molecular Basis of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B. 2001, New York: McGraw-Hill, 3733-3774."},{"issue":"1","key":"2588_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ: High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006, 79 (1): 31-40. 10.1086\/504601.","journal-title":"Am J Hum Genet"},{"key":"2588_CR4","volume-title":"Fabry Disease: Perspectives from 5 Years of FOS","author":"A Mehta","year":"2006","unstructured":"Mehta A, Beck M, Sunder-Plassmann G: Fabry Disease: Perspectives from 5 Years of FOS. 2006, Oxford: Oxford PharmaGenesis Ltd"},{"issue":"7","key":"2588_CR5","first-page":"306","volume":"11","author":"EI Brokalaki","year":"2006","unstructured":"Brokalaki EI, Hentschke M, Grabbe S, Jansen T: Fabry disease in a female patient due to a de novo point mutation at position 691 of exon 5. Eur J Med Res. 2006, 11 (7): 306-308.","journal-title":"Eur J Med Res"},{"issue":"10\u201311","key":"2588_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.clinbiochem.2012.03.015","volume":"45","author":"P Colomba","year":"2012","unstructured":"Colomba P, Nucera A, Zizzo C, Albeggiani G, Francofonte D, Iemolo F, Tuttolomondo A, Pinto A, Duro G: Identification of a novel mutation in the alpha-galactosidase A gene in patients with Fabry disease. Clin Biochem. 2012, 45 (10\u201311): 839-841.","journal-title":"Clin Biochem"},{"issue":"16\u201317","key":"2588_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.clinbiochem.2012.07.085","volume":"45","author":"A Tuttolomondo","year":"2012","unstructured":"Tuttolomondo A, Duro G, Miceli S, et al: Novel alpha-galactosidase A mutation in a female with recurrent strokes. Clin Biochem. 2012, 45 (16\u201317): 1525-1530.","journal-title":"Clin Biochem"},{"key":"2588_CR8","volume-title":"J Nephrol","author":"M Cybulla","year":"2012","unstructured":"Cybulla M, Kurschat C, West M, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S: Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J Nephrol. 2012, doi: 10.5301\/jn.5000214"},{"key":"2588_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R: Fabry disease. Pharmacol Ther. 2009, 122: 65-77. 10.1016\/j.pharmthera.2009.01.003.","journal-title":"Pharmacol Ther"},{"key":"2588_CR10","first-page":"69","volume":"7","author":"M Alfadhel","year":"2011","unstructured":"Alfadhel M, Sirrs S: Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag. 2011, 7: 69-82.","journal-title":"Ther Clin Risk Manag"},{"issue":"Suppl 1","key":"2588_CR11","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0149-2918(07)80116-0","volume":"29","author":"A Raas-Rothschild","year":"2007","unstructured":"Raas-Rothschild A: Pediatrics: implementing the promise of early intervention for Fabry disease. Clin Ther. 2007, 29 (Suppl 1): S6-","journal-title":"Clin Ther"},{"key":"2588_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1542\/peds.2004-1678","volume":"115","author":"M Ries","year":"2005","unstructured":"Ries M, Gupta S, Moore DF, et al: Pediatric Fabry disease. Pediatrics. 2005, 115: 344-355. 10.1542\/peds.2004-1678.","journal-title":"Pediatrics"},{"issue":"323","key":"2588_CR13","first-page":"1","volume":"4","author":"C Bono","year":"2011","unstructured":"Bono C, Nuzzo D, Albeggiani G, Zizzo C, Francofonte D, Iemolo F, Sanzaro E, Duro G: Genetic screening of Fabry patients with EcoTILLING and HRM technology. BMC Res Notes. 2011, 4 (323): 1-7.","journal-title":"BMC Res Notes"},{"key":"2588_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ymgme.2008.09.002","volume":"95","author":"M Erdros","year":"2008","unstructured":"Erdros M, N\u00e9meth K, T\u00f3th B, et al: Novel sequence variants of the \u03b1-galactosidase A gene in patients with Fabry disease. Mol Genet Metab. 2008, 95: 224-228. 10.1016\/j.ymgme.2008.09.002.","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"2588_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","volume":"308","author":"NA Chamoles","year":"2001","unstructured":"Chamoles NA, Blanco M, Gaggioli D: Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001, 308 (1\u20132): 195-196.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"2588_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","volume":"337","author":"SC Garman","year":"2004","unstructured":"Garman SC, Garboczi DN: The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol. 2004, 337 (2): 319-335. 10.1016\/j.jmb.2004.01.035.","journal-title":"J Mol Biol"},{"issue":"4","key":"2588_CR17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/hmg\/3.4.667","volume":"3","author":"J Davies","year":"1994","unstructured":"Davies J, Christomanou H, Winchester B, Malcolm S: Detection of 8 new mutations in the \u03b1-galactosidase A gene in Fabry disease. Hum Mol Genet. 1994, 3 (4): 667-669. 10.1093\/hmg\/3.4.667.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"2588_CR18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","volume":"3","author":"CM Eng","year":"1997","unstructured":"Eng CM, Ashley GA, Burgert TS, Enriquez AL, D\u2019Souza M, Desnick RJ: Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med. 1997, 3 (3): 174-182.","journal-title":"Mol Med"},{"issue":"5","key":"2588_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","volume":"2","author":"J Shabbeer","year":"2006","unstructured":"Shabbeer J, Yasuda M, Benson SD, Desnick RJ: Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics. 2006, 2 (5): 297-309. 10.1186\/1479-7364-2-5-297.","journal-title":"Hum Genomics"},{"issue":"5","key":"2588_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF00223869","volume":"95","author":"T Okumiya","year":"1995","unstructured":"Okumiya T, Ishii S, Kase R, Kamei S, Sakuraba H, Suzuki Y: Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins. Hum Genet. 1995, 95 (5): 557-561.","journal-title":"Hum Genet"},{"key":"2588_CR21","volume-title":"GeneReviews","author":"A Mehta","year":"2011","unstructured":"Mehta A, Hughes DA: Fabry disease. GeneReviews. Edited by: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP. 2011, Seattle (WA): University of Washington, Seattle"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-7-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:40:11Z","timestamp":1630550411000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-7-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2588"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-7-11","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,7]]},"assertion":[{"value":"29 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"11"}}